STRANDDX
DEAD

Serial Number

90842769

Owner

Linus Biotechnology Inc.

Attorney

Michael R Rizzo

Filing Date

Jul 22, 2021

Add to watchlist:

No watchlists yet
View on USPTO

STRANDDX Trademark

Serial Number: 90842769

STRANDDX is a trademark filed by Linus Biotechnology Inc. on July 22, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Linus Biotechnology Inc. (5 trademarks)

83 Woodlawn Avenue
New Rochelle, NY 10804

Entity Type: 03

Trademark Details

Filing Date

July 22, 2021

Registration Date

Not Registered

Published for Opposition

November 22, 2022

Goods & Services

Laboratory diagnostic kits comprised of a test tube for specimen collection and a requisition form for use with an analysis device for testing hair samples for diagnosis of autism spectrum disorder (ASD), attention deficit hyperactive disorder (ADHD), amyotrophic lateral sclerosis (ALS), psychosis, schizophrenia, inflammatory bowel disease (IBS), eosinophilic esophagitis, renal disease, and cancer

Medical diagnostic kits comprising medical diagnostic reagents to be used in exposomic testing; medical diagnostic kits comprising medical diagnostic reagents for diagnosing autism spectrum disorder (ASD), attention deficit hyperactive disorder (ADHD), amyotrophic lateral sclerosis (ALS), psychosis, schizophrenia, inflammatory bowel disease (IBS), eosinophilic esophagitis, renal disease, and cancer; medical diagnostic reagents and assays for testing hair samples

Medical diagnostic testing, monitoring and reporting services; medical testing for diagnostic purposes in the fields of autism spectrum disorder (ASD), attention deficit hyperactive disorder (ADHD), amyotrophic lateral sclerosis (ALS), psychosis, schizophrenia, inflammatory bowel disease (IBS), eosinophilic esophagitis, renal disease, and cancer; genetic testing for medical purposes

Apparatus for exposomic testing for medical purposes; apparatus for analysis of hair samples for medical diagnostic purposes for detecting autism spectrum disorder (ASD), attention deficit hyperactive disorder (ADHD), amyotrophic lateral sclerosis (ALS), psychosis, schizophrenia, inflammatory bowel disease (IBS), eosinophilic esophagitis, renal disease, and cancer; medical apparatus and instrument for diagnostic use, namely, apparatus for medical diagnostic testing for detecting autism spectrum disorder (ASD), attention deficit hyperactive disorder (ADHD), amyotrophic lateral sclerosis (ALS), psychosis, schizophrenia, inflammatory bowel disease (IBS), eosinophilic esophagitis, renal disease, and cancer; medical devices for testing hair samples for diagnostic purposes for detecting autism spectrum disorder (ASD), attention deficit hyperactive disorder (ADHD), amyotrophic lateral sclerosis (ALS), psychosis, schizophrenia, inflammatory bowel disease (IBS), eosinophilic esophagitis, renal disease, and cancer; medical diagnostic kits comprised of blood collecting, urine collecting, and hair sample collecting tubes for specimen collection and a requisition form for use with an analysis device for testing hair samples for diagnosis of autism spectrum disorder (ASD), attention deficit hyperactive disorder (ADHD), amyotrophic lateral sclerosis (ALS), psychosis, schizophrenia, inflammatory bowel disease (IBS), eosinophilic esophagitis, renal disease, and cancer

Medical and scientific research in the fields of autism spectrum disorder (ASD), attention deficit hyperactive disorder (ADHD), amyotrophic lateral sclerosis (ALS), psychosis, schizophrenia, inflammatory bowel disease (IBS), eosinophilic esophagitis, renal disease, and cancer diagnosis; medical research in the fields of autism spectrum disorder (ASD), attention deficit hyperactive disorder (ADHD), amyotrophic lateral sclerosis (ALS), psychosis, schizophrenia, inflammatory bowel disease (IBS), eosinophilic esophagitis, renal disease, and cancer treatment and diagnosis; laboratory research in the fields of autism spectrum disorder (ASD), attention deficit hyperactive disorder (ADHD), amyotrophic lateral sclerosis (ALS), psychosis, schizophrenia, inflammatory bowel disease (IBS), eosinophilic esophagitis, renal disease, and cancer; genetic testing for scientific research purposes

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 30, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 29, 2025 ABN6
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 21, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 21, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 21, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 21, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 21, 2025 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 5, 2025 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 5, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 5, 2025 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 21, 2024 EXRA
SOU EXTENSION 4 GRANTED
Oct 21, 2024 EX4G
SOU EXTENSION 4 FILED
Oct 21, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 21, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 11, 2024 EXRA
SOU EXTENSION 3 GRANTED
Jul 11, 2024 EX3G
SOU EXTENSION 3 FILED
Jul 11, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Jul 11, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 18, 2023 EXRA
SOU EXTENSION 2 GRANTED
Nov 16, 2023 EX2G
SOU EXTENSION 2 FILED
Nov 16, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 16, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 30, 2023 EXRA
SOU EXTENSION 1 GRANTED
Jun 28, 2023 EX1G
SOU EXTENSION 1 FILED
Jun 28, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 28, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 17, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 22, 2022 NPUB
PUBLISHED FOR OPPOSITION
Nov 22, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 2, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 14, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 13, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 12, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 12, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 19, 2022 GNRN
NON-FINAL ACTION E-MAILED
Apr 19, 2022 GNRT
NON-FINAL ACTION WRITTEN
Apr 19, 2022 CNRT
ASSIGNED TO EXAMINER
Apr 18, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 22, 2021 NWOS
NEW APPLICATION ENTERED
Jul 26, 2021 NWAP